Skip to main content
Premium Trial:

Request an Annual Quote

Veridex to Acquire Assets of Immunicon for $31M

NEW YORK (GenomeWeb News) – Johnson & Johnson company Veridex said today that it will acquire substantially all of the assets of cancer diagnostics firm Immunicon for $31 million in cash.
The assets involved in the sale include intellectual property, product inventory, clinical data, and all technologies related to Immunicon’s CellSearch system, which automates the detection and enumeration of circulating tumor cells. The system is currently cleared for the prognosis and monitoring of patients with metastatic breast, metastatic colorectal, and metastatic prostate cancer.
Immunicon is currently in bankruptcy proceedings, and the bankruptcy court overseeing its case must approve the deal. Veridex said that the acquisition price is subject to certain closing adjustments, plus the discharge and release of certain claims owed to Veridex, and the assumption of certain liabilities.
The firms have been collaborators since 2000 in developing cancer diagnostic platforms and products.
In addition to selling CellSearch assays, Veridex also sells GeneSearch assays that use molecular technology.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.